GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response

被引：91

作者：

Chen, Baishen ^{[1
,3
]}

Rao, Xi ^{[4
]}

House, Michael G. ^{[1
]}

Nephew, Kenneth P. ^{[1
,5
]}

Cullen, Kevin J. ^{[2
]}

Guo, Zhongmin ^{[1
,5
]}

机构：

[1] Indiana Univ Sch Med, Med Sci Program, Bloomington, IN USA

[2] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[3] Sun Yat Sen Univ, Dept Surg, Mem Hosp, Sch Med, Guangzhou 510275, Guangdong, Peoples R China

[4] Indiana Univ, Interdisciplinary Biochem Grad Program, Dept Mol & Cellular Biochem, Bloomington, IN USA

[5] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

来源：

CANCER LETTERS | 2011年 / 309卷 / 01期

关键词：

DNA methylation; Antioxidant enzymes; Head and neck cancer; Chemotherapy response; Prognosis; S-TRANSFERASE-PI; NITRIC-OXIDE SYNTHASE; OXIDATIVE DNA-DAMAGE; NECK-CANCER; PROSTATE-CANCER; BREAST-CANCER; CELL-LINES; GLUTATHIONE; HEAD; EXPRESSION;

D O I：

10.1016/j.canlet.2011.05.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glutathione peroxidase 3 (GPx3), a plasma antioxidant enzyme, maintains genomic integrity by inactivating reactive oxygen species (ROS), known DNA-damaging agents and mediators of cancer chemotherapy response. In this study, we demonstrate that loss of GPx3 expression by promoter hypermethylation is frequently observed in a wide spectrum of human malignancies. Furthermore, GPx3 methylation correlates with head and neck cancer (HNC) chemoresistance and may serve as a potential prognostic indicator for HNC patients treated with cisplatin-based chemotherapy. Our findings support the hypothesis that defects in the antioxidant system may contribute to tumorigenesis of a wide spectrum of human malignancies. GPx3 methylation may have implications in chemotherapy response and clinical outcome of HNC patients. Published by Elsevier Ireland Ltd.

引用

页码：37 / 45

页数：9

共 51 条

[1]

[Anonymous], 2006, J CARCINOG, DOI DOI 10.1186/1477-3163-5-14

[2] DNA methylation and gene silencing in cancer [J].

Baylin S.B. .

Nature Clinical Practice Oncology, 2005, 2 (Suppl 1) :S4-S11

[3]

Behrend L, 2003, BIOCHEM SOC T, V31, P1441

[4] Glutathione peroxidases in different stages of carcinogenesis [J].

Brigelius-Flohe, Regina ;

Kipp, Anna .

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2009, 1790 (11) :1555-1568

[5] The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin [J].

Brozovic, Anamaria ;

Ambriovic-Ristov, Andreja ;

Osmak, Maja .

CRITICAL REVIEWS IN TOXICOLOGY, 2010, 40 (04) :347-359

[6] Oxidative damage in an esophageal adenocarcinoma model with rats [J].

Chen, XX ;

Ding, YW ;

Yang, GY ;

Bondoc, F ;

Lee, MJ ;

Yang, CS .

CARCINOGENESIS, 2000, 21 (02) :257-263

[7] Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects [J].

Conklin, KA .

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2000, 37 (01) :1-18

[8] β-Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck: A Companion Analysis of the TAX 324 Trial [J].

Cullen, Kevin J. ;

Schumaker, Lisa ;

Nikitakis, Nikolaos ;

Goloubeva, Olga ;

Tan, Ming ;

Sarlis, Nicholas J. ;

Haddad, Robert I. ;

Posner, Marshall R. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6222-6228

[9]

Cullen KJ, 2003, CANCER RES, V63, P8097

[10]

Davis W, 2001, J PHARMACOL EXP THER, V296, P1

← 1 2 3 4 5 6 →